



ADVANCED/METASTATIC



Open to Accrual



Low Accruing



**Pending Activation** 

ALK


**1L** 

**2**L

**ALK Mutations** 

UCI 21-241 (Nuvalent) NVL-655 + ALK inhibitor

Mechanism: TKI Inhibitor Coord: Keagan Buttigieg Accrual: 13/30



**EGFR Mutations** 

Exon 18

ADVANCED/METASTATIC

Open to Accrual Low Accruing Pending Activation

Exon 19 del or L858R

**1L** 

**2L** 

# UCI 23-95 (HARMONI)

Randomized Double Blind: AK112/Placebo + Pem + Carbo

Mechanism: Novel PD-1/VEGF bispecific antibody w/ Chemo Coord: Celest Ramirez Accrual: 2/8 Mechanism: TKI Coord: Richard Chang Accrual: 0/12

UCI 22-121 (Jintsbio)

JIN-A02 Monotherapy

Amivantamb + Lazertinib w/ or without Carbo + Pemetrexed

UCI 22-217(Janssen)

Mechanism: Antibody drug w/ TKI and Chemo Coord: Celest Ramirez Accrual: 4/10

FR Mutations


EG



#### ADVANCED/METASTATIC Open to Accrual **Pending Activation** Low Accruing

Exon 20 Exon 21

UCI 22-217(Janssen) Amivantamb + Lazertinib w/ or without Carbo + Pemetrexed Mechanism: Antibody drug w/ TKI **1L** and Chemo Coord: Celest Ramirez Accrual: 4/10



**EGFR Mutations** 



Stage 1A / Adjuvant



Open to Accrual



Low Accruing



Pending Activation

## <u>UCI 22-59 (ADAURA)</u>

Randomized: Osimertinib or Placebo


Mechanism: TKI Coord: Jenny Choe Accrual: 1/20



.....

cMET and EGFR

**1L** 



June 2024

6



## ADVANCED/METASTATIC

1L **UCI 23-66 (Boehringer Ingelheim)** BI-1810631 Monotherapy Mechanism: TKI Cord: Keagan Buttigieg Accrual: 0/8 **2**L

Exon 19

Exon 20

#### UCI 21-234 (AstraZeneca)

Randomized: Arm 1: T-DXD(Trastuzumab Deruxtecan) or Arm 2: Cisplatin or Carbo + Pemetrexed + Pembrolizumab

- \*Treatment Naïve for palliative intent systemic therapy in locally advanced or metastatic disease.
- \*Documented Her2 Exon 19 or 20 mutation
- \*Tumor sample must be available for central testing from fresh or archival.
- \*No Slot Required prior to consenting if mutation of HER2 is available.

Accrual: 1/20

## ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pe

**Pending Activation** 

## KRAS G12C

11

#### UCI 22-30 (D3S-001-100):

D3 Bio

Mechanism: TKI Coord: Richard Chang Accrual: 0/5

2L

**KRAS MUTATIONS** 

#### UCI 22-88 (RMC-6291 Revolution Med)

Mechanism: TKI Coord: Richard Chang Accrual: 4/30

UCI 21-53 (Loxo Oncology, Inc. LOXO-RAS-20001

Mechanism: TKI Coord: Jenny Choe Accrual: 6/16 UCI 23-116 (RMC-6291 Revolution Medicine)

> Mechanism: TKI Coordinator: TBD Accural: 0/15

UCI 18-78 (Mirati MRTX-849)

Mechanism: TKI Coord: Celest Ramirez 24/50 G12A, G12D, G12R, G12S, G12V

> UCI 22-87 (RMC-6236 Revolution Med)

Mechanism: TKI Coordinator: Oliver Quines Accrual: 14/30







Low Accruing



## ADVANCED/METASTATIC

#### NRG-LU007

Treatment: (Randomized) Group 1: Atezolizumab Alone. Group 2: Atezolizumab + Radiation

Mechanism: Immunotherapy + Radiation Coord: Richard Chang Accrual: 1/10

#### **UCI 23-178**

Treatment: BL-B01D1 IV
Mechanism: IP binding to EGFR/HER3,
antibody fragments of IP bind to
EGFR/HER3, Fc segment of (ADCC)
Coord: TBA
Accrual: 0/17



**NTRK Mutations** 

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

**Pending Activation** 

NTRK 1-3

**1L** 



All Comers

**3L** 

**NTRK Mutations** 

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ROR2

**1**L

2L



**ROS1 Mutations** 

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

**Pending Activation** 

ROS1

**1L** 

**UCI 21-47 ( NVL-520 Nuvalent) 2**L Mechanism: TKI Coord: Keagan Buttigieg Accrual: 9/28







Low Accruing

Pending Activation

# **Database & Repository**

UCI 21-238: Database & Repository of Asian female never smokers w/ low dose CT scan Screening Study

> Mechanism: D Coord: TBD Accrual: 0/100



# Open to Accrual

Pending Activation Low Accruing

# **Advanced / Metastatic**

**1L** 

UCI 21-242: Ph III Durvalumab Combo w/Dato-DXd vs Pembro

> Mechanism: Chemo + experimental drug Coord: Celest Ramirez Accrual: 0/12

**2L** 

UCI 23-148: CJRB-01 (oral) + Pembrolizumab

Mechanism: Live biotherapeutic product containing a novel strain belonging in the species Leuconostoc mesenteroides (L. mesenteroides + Pembrolizumab Coord: TBD Accrual: 0/12










Low Accruing





Mechanism: Fecal Collection Coord: Stefanie Fernandez Accrual: 1/100

